Breaking News Instant updates and real-time market news.

ABT

Abbott

$40.71

-0.37 (-0.90%)

16:01
01/12/17
01/12
16:01
01/12/17
16:01

Abbott launches new EnSite Precision Cardiac mapping system in U.S.

Abbott announced the U.S. launch and the first commercial uses of the new EnSite Precision cardiac mapping system and Advisor FL Circular Mapping Catheter, Sensor Enabled to map cardiac arrhythmias during ablation treatments. The first commercial use of the system after U.S. FDA clearance occurred at the Intermountain Heart Institute at Intermountain Medical Center in Salt Lake City during ablation procedures conducted by electrophysiologist John Day, M.D. Since the landmark clinical cases by Dr. Day, additional procedures supported by the new EnSite Precision cardiac mapping system have occurred in 12 states nationwide, supporting ablation procedures to treat complex arrhythmias. Abbott expects its new cardiac mapping technology to quickly become a new standard for use in treating patients experiencing arrhythmias from multiple origins in the heart. In the coming weeks, physicians across the country will begin to use the EnSite Precision cardiac mapping system.

  • 25

    Jan

  • 21

    Feb

ABT Abbott
$40.71

-0.37 (-0.90%)

10/20/16
LEER
10/20/16
NO CHANGE
Target $45
LEER
Market Perform
Abbott selloff overdone as long-term fundamentals remain intact, says Leerink
Leerink analyst Danielle Antalffy believes the selloff in Abbott's shares is overdone, as long-term fundamentals remain intact. With another "solid" quarter in hand, despite a weaker than expected Nutritionals performance, the analyst believes the company seems to remain "solidly" on track to deliver improving operational results in 2017, after a year in which it is reshaping the portfolio by acquiring higher-growth assets and shedding slower, lower-margin businesses. Antalffy reiterates a Market Perform rating on the stock but lowered her price target on the shares to $45 from $48.
10/25/16
RBCM
10/25/16
NO CHANGE
RBCM
Abbott should be bought on recent weakness, says RBC Capital
After Abbott reported slightly stronger than expected Q3 results, RBC Capital analyst Glenn Novarro predicts that the company's 2016 EPS will come in at $2.63, excluding its acquisition of Alere. The analyst thinks that Abbott's EPs can rise to $2.93 in 2018, excluding the Alere deal, driven by lower interest costs and higher synergies. He says that recent weakness in the stock has been caused by issues that are "either transient or can be offset." The analyst keeps a $48 price target and Outperform rating on the stock.
12/08/16
ADAM
12/08/16
NO CHANGE
Target $52
ADAM
Buy
Legal rights in favor of Alere in buyout fight, says Canaccord
Canaccord analyst Mark Massaro noted Abbot (ABT) filed a lawsuit to terminate its acquisition of Alere (ALR), which sent the latter's stock below where it was prior to the original deal being struck. The analyst said the legal jurisdiction is in Delaware, which heavily favors Alere, who said they will take whatever actions are necessary to make Abbott complete the transaction. Alere is confident the deal will be completed at the agreed upon terms, with the company in a good position to have its Arriva Medical business reimbursement restored by the CMS, said Massaro, who raised his price target to $52 from $50 and reiterated his Buy rating on Alere shares.
12/19/16
12/19/16
UPGRADE
Target $84

Outperform
Dexcom upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Steven Lichtman upgraded Dexcom (DXCM) to Outperform from Perform, with an $84 price target, given valuation reflecting competitive concerns and big long-term opportunities in place. While new competition in the U.S. is expected from Medtronic (MDT) and likely Abbott (ABT) and Senseonics (SENS) in 2017, the analyst believes the CGM market remains underpenetrated in Type 1 patients, a dosing claim is expected early 2017, international reimbursement should be a growing tailwind and 2018 brings new growth drivers with expected launch of Dexcom's next-generation G6 and potential Medicare expansion.

TODAY'S FREE FLY STORIES

ADBE

Adobe

$175.00

-1.83 (-1.03%)

07:15
12/15/17
12/15
07:15
12/15/17
07:15
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIGL

Rigel Pharmaceuticals

$3.57

-0.15 (-4.03%)

07:14
12/15/17
12/15
07:14
12/15/17
07:14
Initiation
Rigel Pharmaceuticals initiated  »

Cantor sees FDA approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

CRTO

Criteo

$24.42

-7.19 (-22.75%)

07:12
12/15/17
12/15
07:12
12/15/17
07:12
Downgrade
Criteo rating change  »

Criteo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$50.19

0.14 (0.28%)

07:11
12/15/17
12/15
07:11
12/15/17
07:11
Recommendations
Oracle analyst commentary  »

Oracle business momentum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIPR

Innovative Industrial Properties

$22.60

2.28 (11.22%)

07:10
12/15/17
12/15
07:10
12/15/17
07:10
Hot Stocks
Innovative Industrial Properties raises quarterly dividend to 25c per share »

Innovative Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLX

Hologic

$42.96

-0.72 (-1.65%)

07:08
12/15/17
12/15
07:08
12/15/17
07:08
Recommendations
Hologic analyst commentary  »

Hologic positioned well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFGC

Performance Food Group

$30.55

-0.9 (-2.86%)

07:07
12/15/17
12/15
07:07
12/15/17
07:07
Earnings
Performance Food Group sees FY18 adjusted EPS up 13%-18% »

For fiscal 2018, PFG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

TYME

Tyme Technologies

$3.30

0.05 (1.54%)

07:05
12/15/17
12/15
07:05
12/15/17
07:05
Initiation
Tyme Technologies initiated  »

Tyme Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

, SNY

Sanofi

$43.09

-0.83 (-1.89%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Hot Stocks
Alnylam announces lift of FDA clinical hold on Fitusiran »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

SNY

Sanofi

$43.09

-0.83 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

  • 02

    May

UA

Under Armour; also tag UAA

$12.45

0.09 (0.73%)

, UAA

Under Armour; also tag UA

$13.82

0.2 (1.47%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Upgrade
Under Armour; also tag UAA, Under Armour; also tag UA rating change  »

Under Armour upgraded to…

UA

Under Armour; also tag UAA

$12.45

0.09 (0.73%)

UAA

Under Armour; also tag UA

$13.82

0.2 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBA

Ritchie Bros.

$28.69

0.3 (1.06%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Hot Stocks
Ritchie Bros. sess $50M+ of equipment in final Fort Worth, TX auction of 2017 »

This week Ritchie Bros.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$43.09

-0.83 (-1.89%)

, ALNY

Alnylam

$123.66

-1.2 (-0.96%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
Sanofi says FDA lifts clinical hold on fitusiran »

Sanofi Genzyme, the…

SNY

Sanofi

$43.09

-0.83 (-1.89%)

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

  • 02

    May

CROX

Crocs

$10.94

-0.34 (-3.01%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Upgrade
Crocs rating change  »

Crocs upgraded to Buy on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 08

    Jan

ESNC

EnSync

$0.44

0.0663 (17.79%)

, CHTR

Charter

$328.68

-0.32 (-0.10%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
EnSync: Spectrum solar plus storage project commissioned in Hawaii »

EnSync (ESNC) announces…

ESNC

EnSync

$0.44

0.0663 (17.79%)

CHTR

Charter

$328.68

-0.32 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

PFGC

Performance Food Group

$30.55

-0.9 (-2.86%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
Performance Food Group appoints Jim Hope as CFO »

Performance Food Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

ACRS

Aclaris Therapeutics

$24.72

-0.38 (-1.51%)

07:02
12/15/17
12/15
07:02
12/15/17
07:02
Hot Stocks
Aclaris Therapeutics receives FDA approval for Eskata topical solution, 40% »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

AER

AerCap

$52.12

-0.46 (-0.87%)

07:01
12/15/17
12/15
07:01
12/15/17
07:01
Recommendations
AerCap analyst commentary  »

AerCap book value can hit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTWO

Q2 Holdings

$37.30

-0.75 (-1.97%)

07:00
12/15/17
12/15
07:00
12/15/17
07:00
Recommendations
Q2 Holdings analyst commentary  »

Q2 Holdings has strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

07:00
12/15/17
12/15
07:00
12/15/17
07:00
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

$6.82

-0.2 (-2.85%)

06:59
12/15/17
12/15
06:59
12/15/17
06:59
Downgrade
Fitbit rating change  »

Fitbit downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,174.80

10.61 (0.91%)

06:55
12/15/17
12/15
06:55
12/15/17
06:55
Periodicals
Luxembourg appeals EU order to recover tax from Amazon, Reuters reports »

Luxembourg is appealing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

ACRS

Aclaris Therapeutics

$24.72

-0.38 (-1.51%)

06:55
12/15/17
12/15
06:55
12/15/17
06:55
Hot Stocks
Breaking Hot Stocks news story on Aclaris Therapeutics »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

GDX

Market Vector Gold Miners

$22.07

-0.09 (-0.41%)

06:54
12/15/17
12/15
06:54
12/15/17
06:54
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$110.57

2.96 (2.75%)

, FOXA

21st Century Fox

$34.88

2.13 (6.50%)

06:54
12/15/17
12/15
06:54
12/15/17
06:54
Recommendations
Disney, 21st Century Fox analyst commentary  »

Disney price target…

DIS

Disney

$110.57

2.96 (2.75%)

FOXA

21st Century Fox

$34.88

2.13 (6.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

GLD

SPDR Gold Trust

$118.93

-0.24 (-0.20%)

06:54
12/15/17
12/15
06:54
12/15/17
06:54
Technical Analysis
SPDR Gold Trust: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.